AIM2 and systemic lupus erythematosus: The DM-SE gene list we prioritized may be a useful tool in grouping SLE patients into DA receptor groups, or “endotypes” as they have been termed by Mustelin et al. [68] Therapies targeting helicases such as RIG-I, MAVS, or AIM2 could prove useful for SLE.